

2011

英文論文

1. 2011 Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, **Kudo M**, Nishio K: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. **Mol Cancer Ther** 10: 169-177, 2011 (IF=5.579).
2. 2011 **Kudo M**, Hatanaka K, Kumada T, Toyoda H, Tada T: Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. **Am J Gastroenterol** 106: 368-370, 2011 (IF=10.383).
3. 2011 Kudo K, Arao T, Tanaka K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, Velasco M, Fujita Y, Saijo N, **Kudo M**, Nishio K: Antitumor activity of BIBF 1120, a vascular endothelial growth factor-2 inhibitor and use of VEGFR2+pTYR+leucocyte as a pharmacodynamic biomarker. **Clin Cancer Res** 17: 1373-1381, 2011 (IF=8.738).
4. 2011 Hagiwara S, **Kudo M**^{*}, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park AM, Munakata H: The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+pegylated interferon α -2b therapy against advanced hepatocellular carcinoma. **J Gastroenterol** 46: 212-221, 2011 (IF=4.414).
5. 2011 Sakamoto H, Kitano M, Matsui S, Kamata K, Komaki T, Imai H, Dote K, **Kudo M**: Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS. **Gastrointest Endosc** 73: 227-237, 2011 (IF=6.217).
6. 2011 Kagawa Y, Okada M, Kumano S, Katsube T, Imaoka I, Tanigawa

- N, Ishii K, **Kudo M**, Murakami T: Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR. **J Magn Reson Imaging** 33: 864-872, 2011 (IF=3.250).
7. 2011 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokmi M, **Kudo M**: Management of hepatitis B: Consensus of Japan Society of Hepatology 2009. **Hepatol Res** 41: 1-21, 2011 (IF=2.208).
8. 2011 Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, **Kudo M**, Kitagaki H, Murakami T: Estimation of liver function using T1 mapping onGd-EOB-DTPA-enhanced magnetic resonance imaging. **Invest Radiol** 46: 277-283, 2011 (IF=4.887).
9. 2011 **Kudo M**, Yamao K, Shimosegawa T: The prognosis of patients with pancreatic cancer is extremely poor. Prefece. **Pancreatology** 11: 1-2, 2011 (IF=2.406).
10. 2011 Sakurai T, **Kudo M**, Fukuta N, Nakatani T, Kimura M, Park AM, Munakata H: Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis. **Pancreatology** 11: 7-13, 2011 (IF=2.406).
11. 2011 Kitano M, **Kudo M**, Sakamoto H, Komaki T: Endoscopic ultrasonography and contrast-enhanced endoscopic. **Pancreatology** 11: 28-33, 2011 (IF=2.406).
12. 2011 Komaki T, Kitano M, Sakamoto H, **Kudo M***: Endoscopic ultrasonography-guided biliary drainage: evaluation of a choledochoduodenostomy technique. **Pancreatology** 11: 47-51, 2011 (IF=2.406).
13. 2011 Sakamoto H, Kitano M, Komaki T, Imai H, Kamata K, **Kudo M**: Endoscopic ultrasound-guided neurolysis in pancreatic cancer.

Pancreatology 11: 52-58, 2011 (IF=2.406).

14. 2011 Minami Y, **Kudo M***: Radiofrequency ablation of hepatocellular carcinoma: A literature review. **Int J Hepatol** 2011: 9pages (104685), 2011 (IF=0.000).
15. 2011 Eguchi S, Kanematsu T, Arii S, Omata M, **Kudo M**, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M, for the Liver Cancer Study Group of Japan: Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. **Brit J Surg** 98: 552-557, 2011 (IF=5.596).
16. 2011 Kitano M, Sakamoto H, Komaki T, **Kudo M**: New techniques and future perspective of EUS for the differential diagnosis of pancreatic malignancies; Contrast harmonic imaging. **Digest Endosc** 23: 46-50, 2011 (IF=2.715).
17. 2011 **Kudo M***: Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. **Digest Dis** 29: 273-277, 2011 (IF=1.777).
18. 2011 **Kudo M***: Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. **Digest Dis** 29: 289-302, 2011 (IF=1.777).
19. 2011 **Kudo M***: mTOR inhibitor for the treatment of hepatocellular carcinoma. **Digest Dis** 29: 310-315, 2011 (IF=1.777).
20. 2011 **Kudo M***: Future treatment option for hepatocellular carcinoma: a focus on brivanib. **Digest Dis** 29: 316-320, 2011 (IF=1.777).
21. 2011 Ueshima K, **Kudo M***, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T: Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of Sorafenib for hepatocellular carcinoma. **Digest Dis** 29: 321-325,

2011 (IF=1.777).

22. 2011 Hayaishi S, Chung H, **Kudo M**^{*}, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K: Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. **Digest Dis** 29: 326-332, 2011 (IF=1.777).
23. 2011 **Kudo M**^{*}, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M: Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guideline proposed by the Japan Society of Hepatology (JSH) 2010 updated version. **Digest Dis** 29: 339-364, 2011 (IF=1.777).
24. 2011 Yoshida H, Shiratori Y, **Kudo M**, Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsujii K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Hokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M, Omata M: Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. **Hepatology** 54: 532-540, 2011 (IF=11.711).
25. 2011 Chung H, Watanabe T, **Kudo M**, Chiba T: Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection. **J Viral Hepat** 18: e561-567, 2011 (IF=4.179).
26. 2011 Kashida H, Ikehara N, Hamatani S, Kudo SE, **Kudo M**^{*}: Endoscopic characteristics of colorectal serrated lesions. **Hepato Gastroenterology** 58: 1163-1167, 2011 (IF=0.792).
27. 2011 **Kudo M**^{*}, Imanaka K, Chiba N, Nakachi K, Tak WT, Takayama T,

Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K: Phase III study of Sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. **Eur J Cancer** 47: 2117-2127, 2011 (IF=6.163).

28. 2011 Llovet JM, Paradis V, **Kudo M**, Zucman-Rossi J: Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. **Liver Transplant** 17: S67-71, 2011 (IF=3.951).
29. 2011 **Kudo M***: Tailor-made therapy for viral hepatitis: Recent advances. **Digestion** 84: 1-4, 2011 (IF=1.884).
30. 2011 Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, Hotta H, Maekawa Y, Hayashi Y, **Kudo M**: Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load. **Digestion** 84: 5-9, 2011 (IF=1.884).
31. 2011 Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasaegawa Y, Fujinami A, Ohta M, Ei-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, Hotta H, **Kudo M**: Double-filtration plasmapheresis plus interferon- β for HCV-1b patients with non-sustained virological response to previous combination therapy. **Digestion** 84: 10-16, 2011 (IF=1.884).
32. 2011 Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, **Kudo M**: Clinical characteristics of non-B non-C hepatocellular carcinoma: A single-center retrospective study. **Digestion** 84: 43-49, 2011 (IF=1.884).

33. 2011 Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, **Kudo M***: Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy. **Digestion** 84: 56-61, 2011 (IF=1.884).
34. 2011 **Kudo M***: Hepatocellular carcinoma in 2011 and beyond: From the pathogenesis to molecular targeted therapy. **Oncology** 81: 1-10, 2011 (IF=2.152).
35. 2011 Sakurai T, **Kudo M**: Signaling pathways governing tumor angiogenesis. **Oncology** 81: 24-29, 2011 (IF=2.152).
36. 2011 Sakurai T, **Kudo M**, Itoh K, Ryu U, Higashitsuji H, Fujita J: Adriamycin enhances proteasome-mediated generation of the proapoptotic processed form of MAGE-A4 in hepatoma cells. **Oncology** 81: 30-35, 2011 (IF=2.152).
37. 2011 **Kudo M***: Adjuvant therapy after curative treatment for hepatocellular carcinoma. **Oncology** 81: 50-55, 2011 (IF=2.152).
38. 2011 Alaboudy A, Inoue T, Hatanak K, Chung H, Hyodo T, Kumano S, Murakami T, Moustafa EFA, **Kudo M**: Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography. **Oncology** 81: 66-72, 2011 (IF=2.152).
39. 2011 **Kudo M***: Diagnostic imaging of hepatocellular carcinoma: Recent progress. **Oncology** 81: 73-85, 2011 (IF=2.152).
40. 2011 Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S,

Sakamoto A, Saito S, Kita R, Kimura T, Osaki Y, **Kudo M**: Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with Sorafenib: A case report. **Oncology** 81: 152-157, 2011 (IF=2.152).

41. 2011 Han KH, **Kudo M**, Ye SL, Choi JY, Poon RTP, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL: Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. **Oncology** 81: 158-164, 2011 (IF=2.152).
42. 2011 Kim SR, Yang J, **Kudo M**, Hino O: Recent advances in the management of chronic hepatitis B. **Hepat Mon** 11: 601-611, 2011 (IF=1.932).
43. 2011 Minami Y, **Kudo M***: Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. **World J Gastroenterol** 17: 4952-4959, 2011 (IF=2.787).
44. 2011 Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, **Kudo M**, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T; the Liver Cancer Study Group of Japan: Demonstration of quality of care measurement using the Japanese liver cancer registry. **Hepatol Res** 41: 1208-1215, 2011 (IF=2.208).
45. 2011 Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, **Kudo M**, Mizokami M, Sakamoto A: Phenotype-dependent production of des- γ -carboxy prothrombin in hepatocellular carcinoma. **J Gastroenterol** 46: 1219-1229, 2011 (IF=4.414).
46. 2011 Bridges JF, Joy SM, Gallego G, **Kudo M**, Ye SL, Han KH, Cheng AL, Blauvelt BM: Needs for hepatocellular carcinoma control policy in the Asia-pacific region. **Asian Pac J Cancer Prev** 12:

2585-2591, 2011 (IF=2.514).

47. 2011 Bridges JF, Gallego G, **Kudo M**, Okita K, Han KH, Ye SL, Blauvelt BM: Identifying and prioritizing strategies for comprehensive liver cancer control in Asia. **BMC Health Serv Res** 11: 298 (12p), 2011 (IF=1.606).